|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -59.35% |
|
-.--% | - |
| 12-16 | Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 12-02 | Top Midday Decliners | MT |
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Revenues | 484K | 350K | 148K | 18.63K | 1M | |||
Total Revenues | 484K | 350K | 148K | 18.63K | 1M | |||
Cost of Goods Sold, Total | 16.63M | 21.44M | 11.81M | 5.74M | 8.36M | |||
Gross Profit | -16.15M | -21.09M | -11.67M | -5.72M | -7.36M | |||
Selling General & Admin Expenses, Total | 8.94M | 8.58M | 7.13M | 6.13M | 8.49M | |||
R&D Expenses | - | - | - | - | - | |||
Other Operating Expenses, Total | 8.94M | 8.58M | 7.13M | 6.13M | 8.49M | |||
Operating Income | -25.09M | -29.67M | -18.79M | -11.85M | -15.84M | |||
Interest Expense, Total | - | - | - | - | -556K | |||
Interest And Investment Income | 15 | - | - | - | - | |||
Net Interest Expenses | 15 | - | - | - | -556K | |||
Currency Exchange Gains (Loss) | -22.04K | -52.48K | -40.08K | 84.29K | -113K | |||
Other Non Operating Income (Expenses) | - | - | - | 4.33M | 720K | |||
EBT, Excl. Unusual Items | -25.11M | -29.72M | -18.83M | -7.44M | -15.79M | |||
In Process R&D Expenses | - | - | - | - | - | |||
Other Unusual Items | 126K | - | - | - | - | |||
EBT, Incl. Unusual Items | -24.98M | -29.72M | -18.83M | -7.44M | -15.79M | |||
Income Tax Expense | - | - | - | - | 218K | |||
Earnings From Continuing Operations | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
Net Income to Company | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
Net Income - (IS) | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||
Net Income to Common Incl Extra Items | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
Net Income to Common Excl. Extra Items | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
Per Share Items | ||||||||
Net EPS - Basic | - | -1.2K | -145.12 | -11.35 | -3.92 | |||
Basic EPS - Continuing Operations | - | -1.2K | -145.12 | -11.35 | -3.92 | |||
Basic Weighted Average Shares Outstanding | - | 24.7K | 130K | 655K | 4.08M | |||
Net EPS - Diluted | - | -1.2K | -145.12 | -11.35 | -3.92 | |||
Diluted EPS - Continuing Operations | - | -1.2K | -145.12 | -11.35 | -3.92 | |||
Diluted Weighted Average Shares Outstanding | - | 24.7K | 130K | 655K | 4.08M | |||
Normalized Basic EPS | - | -751.92 | -90.7 | -7.09 | -2.42 | |||
Normalized Diluted EPS | - | -751.92 | -90.7 | -7.09 | -2.42 | |||
Supplemental Items | ||||||||
EBITDA | -25.07M | -29.66M | -18.78M | -11.84M | -15.83M | |||
EBITA | -25.09M | -29.67M | -18.79M | -11.85M | -15.84M | |||
EBIT | -25.09M | -29.67M | -18.79M | -11.85M | -15.84M | |||
EBITDAR | -24.96M | -29.56M | -18.68M | -11.74M | -15.74M | |||
Effective Tax Rate - (Ratio) | - | - | - | - | -1.38 | |||
Normalized Net Income | -15.69M | -18.58M | -11.77M | -4.65M | -9.87M | |||
Interest on Long-Term Debt | - | - | - | - | - | |||
Supplemental Operating Expense Items | ||||||||
General and Administrative Expenses | 8.94M | 8.58M | 7.13M | 6.13M | 8.49M | |||
Research And Development Expense From Footnotes | 16.63M | 21.44M | 11.81M | 5.74M | 8.36M | |||
Net Rental Expense, Total | 115K | 100K | 96.82K | 92.31K | 94.12K | |||
Imputed Operating Lease Interest Expense | - | - | - | - | 4.72M | |||
Imputed Operating Lease Depreciation | - | - | - | - | -4.63M | |||
Stock-Based Comp., COGS (Total) | 423K | 438K | 121K | 109K | 66.9K | |||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||
Stock-Based Comp., G&A Exp. (Total) | 953K | 438K | 127K | 122K | 133K | |||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||
Total Stock-Based Compensation | 1.38M | 876K | 249K | 231K | 200K |
- Stock Market
- Stocks
- SONN Stock
- Financials Sonnet Biotherapeutics
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















